Sera Prognostics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Sera Prognostics, a women's health company, reported a reduced net loss in 2025, bolstered by a recent capital raise and positive clinical trial results for its PreTRM test, while expanding its executive team and product pipeline.
NASDAQ
Sera Prognostics' 2024 10-K filing details the company's financial performance and strategic advancements, particularly regarding its PreTRM test for preterm birth risk prediction.
NASDAQ
Sera Prognostics has updated its non-employee director compensation policy and filed its annual report on Form 10-K for the fiscal year ended December 31, 2023.